Mobile Menu
Deals & Transactions

Conyers advises Myovant Sciences Ltd. on their US$218 million IPO

Conyers Dill & Pearman advised Myovant Sciences Ltd. on a highly successful underwritten initial public offering on NYSE of 14,500,000 of its shares, for a total fundraising of US$218 million. Roivant Sciences Ltd., the parent company, remains the majority shareholder. This is the biggest New York IPO in the biotechnology sector so far in 2016 and is the latest biotechnology IPO to use a Bermuda company as the listing vehicle.

Neil Henderson, Robert Alexander and Edward Rance worked on the matter with Cooley LLP acting as US counsel to the issue and Latham & Watkins LLP acting as US counsel to the underwriters.

 


Neil Henderson
Director

BERMUDA   +1 441 298 7846



Edward Rance
Associate

Bermuda   +1 441 278 7904


Accolades
_

"Few firms can come close to Conyers on one critical metric, and this is the breadth of the client base."
- IFLR1000

Related Jurisdictions

Bermuda


Related International Offices

Bermuda


Media Contact

For media enquiries, please contact media@conyersdill.com

Deals & Transactions

Conyers advises Myovant Sciences Ltd. on their US$218 million IPO

Conyers Dill & Pearman advised Myovant Sciences Ltd. on a highly successful underwritten initial public offering on NYSE of 14,500,000 of its shares, for a total fundraising of US$218 million. Roivant Sciences Ltd., the parent company, remains the majority shareholder. This is the biggest New York IPO in the biotechnology sector so far in 2016 and is the latest biotechnology IPO to use a Bermuda company as the listing vehicle.

Neil Henderson, Robert Alexander and Edward Rance worked on the matter with Cooley LLP acting as US counsel to the issue and Latham & Watkins LLP acting as US counsel to the underwriters.

 


Neil Henderson
Director

BERMUDA   +1 441 298 7846



Edward Rance
Associate

Bermuda   +1 441 278 7904


 

JURISDICTION(S)

Bermuda


International Office(s)

Bermuda